Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
| dc.contributor.author | Flaum, Nicola | |
| dc.contributor.author | Valle, Juan W | |
| dc.contributor.author | Mansoor, Was | |
| dc.contributor.author | McNamara, Mairéad G | |
| dc.date.accessioned | 2016-09-06T09:50:58Z | |
| dc.date.available | 2016-09-06T09:50:58Z | |
| dc.date.issued | 2016-07-14 | |
| dc.identifier.citation | Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. 2016: Future Oncol | en |
| dc.identifier.issn | 1744-8301 | |
| dc.identifier.pmid | 27412069 | |
| dc.identifier.doi | 10.2217/fon.16.23 | |
| dc.identifier.uri | http://hdl.handle.net/10541/619878 | |
| dc.description.abstract | Neuroendocrine tumors (NETs) are a rare diverse group of malignancies occurring most commonly in the gastroenteropancreatic system and the lungs. The incidence of NETs is increasing worldwide; median survival for patients with metastatic NETs is 5-65 months. A growing body of evidence shows survival benefit in patients with advanced NETs (gastroenteropancreatic and lung) treated with mTOR inhibitor everolimus, with improvement in survival being demonstrated in the clinical trial and real-world setting. Everolimus has been shown to have a manageable safety profile, with the most common adverse events being stomatitis, rash, diarrhea, fatigue and infections. Due to the rarity of the condition, there are challenges in conducting clinical trials in these patients. Further research is required to clarify the role of adjuvant therapy, treatment sequencing and the use of multimodality treatments. | |
| dc.language | ENG | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Future oncology (London, England) | en |
| dc.title | Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. | en |
| dc.type | Article | en |
| dc.contributor.department | "Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, | en |
| dc.identifier.journal | Future Oncology | en |
| html.description.abstract | Neuroendocrine tumors (NETs) are a rare diverse group of malignancies occurring most commonly in the gastroenteropancreatic system and the lungs. The incidence of NETs is increasing worldwide; median survival for patients with metastatic NETs is 5-65 months. A growing body of evidence shows survival benefit in patients with advanced NETs (gastroenteropancreatic and lung) treated with mTOR inhibitor everolimus, with improvement in survival being demonstrated in the clinical trial and real-world setting. Everolimus has been shown to have a manageable safety profile, with the most common adverse events being stomatitis, rash, diarrhea, fatigue and infections. Due to the rarity of the condition, there are challenges in conducting clinical trials in these patients. Further research is required to clarify the role of adjuvant therapy, treatment sequencing and the use of multimodality treatments. |